Intersectional and complementary small molecule and RNAi screening allowed us to identify AURKB as a therapeutic target and develop the nanoparticle AURKB inhibitor AZD2811NP as a novel treatment approach for MCC. The gene discussed is AURKB; the disease is Merkel cell skin cancer.